Engraftment syndrome following Hematopoietic stem cell transplantation: a systematic approach toward diagnosis and management.
Shahzaib MaqboolMuhammad NadeemAhmad ShahrozKiran NaimatImran KhanHassaan TahirAbdur RehmanFaiz AnwerRaheel IftikharKa Yiu LeePublished in: Medical oncology (Northwood, London, England) (2022)
Engraftment syndrome (ES) is a non-infectious complication seen both in autologous and allogeneic hematopoietic stem cell transplants and is characterized by the presence of non-infectious fever, diarrhea, skin rash, pulmonary infiltration, pulmonary edema, and deranged renal and liver function tests This review will be delineating the incidence of ES, important differential diagnoses to be considered and management options. The literature search was done through various databases like PubMed, Google scholar, Cochrane library, and EMBASE. The incidence of engraftment syndrome was ranging from 8 to 50% in patients undergoing Autologous stem cell transplantation while the incidence was 10-77% in patients undergoing Allogeneic stem cell transplantation. Fever was the most commonly observed symptom of ES in both Autologous and Allogeneic stem cell transplantation while the second most frequently reported symptom was non-infectious diarrhea in patients undergoing autologous stem cell transplantation and Skin rash in patients with Allogeneic stem cell transplantation. Pro-inflammatory cytokines and immune response dysregulation were highlighted as the mechanism behind ES development. The significant difference between ES and aGVHD was observed based on cytokines, with IL-12, IL-1β, IL-6, TNF-α, and IFN-γ levels in plasma being higher in patients with ES as compared to patients with aGVHD. Intravenous methylprednisolone was used as the treatment of choice in the majority of the studies. Overall the incidence of ES was high in patients undergoing allogeneic hematopoietic stem cells transplantation. The survival in patients developing ES was less compared to those who did not develop ES. Engraftment syndrome is one of the complications following hematopoietic stem cell transplantation that need early identification, differentiation from infectious complications, and aGVHD and timely initiation of corticosteroids therapy.
Keyphrases
- stem cell transplantation
- high dose
- patients undergoing
- hematopoietic stem cell
- risk factors
- stem cells
- cell therapy
- bone marrow
- immune response
- case report
- acute myeloid leukemia
- pulmonary hypertension
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- systematic review
- dendritic cells
- ejection fraction
- platelet rich plasma
- inflammatory response
- machine learning
- patient reported
- clostridium difficile
- cord blood
- free survival